Owners (and spouses) Tei Fu Chen and Oi-Lin Chen started Sunrider International in 1982. Sunrider Corporation has blended bits of traditional Chinese herbal medicine with modern multilevel marketing. The company sells health, beauty, food, and household products enhanced with herbs and herbal extracts. Its brands include Kandesn, Vitalite, SunBright, and SunSmile. Sunrider has manufacturing operations in China, Singapore, Taiwan, and the US. Its products are sold in more than 40 countries through multilevel marketing via distributors and directly to customers. In China, its products are sold in thousands of franchised stores to avoid regulations on direct-selling. It plans to copy that model in Japan.

Novavax, Inc. was founded in 1987 and is headquartered in Rockville, Maryland. Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing vaccines using its virus-like particle platform technology for infectious diseases. It develops vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, and Respiratory Syncytial Virus, as well as Varicella Zoster that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza virus-like-particle-based vaccine candidates and therapeutic vaccine candidates against cancer, as well as adjuvants, biogeneric products, and other diagnostic products for the territory of India. It also has a strategic collaboration Xcellerex Inc. for the production of 2009 H1N1 influenza vaccine.

Idera Pharmaceuticals, Inc. company was founded in 1989 and is based in Cambridge, Massachusetts. Idera Pharmaceuticals, Inc., a biotechnology company, discovers and develops DNA- and RNA-based drug candidates for the treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and asthma and allergies, and for use as vaccine adjuvants. The company designs and creates proprietary Toll-Like Receptors (TLR) to modulate immune responses, including TLR agonist, a compound that stimulates an immune response through the targeted TLR; and TLR antagonist, a compound that blocks activation of an immune response through the targeted TLR. Its drug candidates include IMO-2125, a TLR9 agonist, which is in Phase 1 clinical trial for hepatitis C virus infection; and TLR7, 8, and 9 agonists that are in research stage for viral diseases. The company also develops IMO-3100, a dual TLR7/TLR9 antagonist, which is in preclinical development stage for autoimmune and inflammatory diseases, such as lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, and colitis.In addition, its drug candidates also comprise TLR7 and TLR8 agonists that are in research stage for solid tumor cancers. The company has a licensing and collaboration agreement with Merck KGaA to research, develop, and commercialize TLR9 agonists for the treatment of cancer, excluding cancer vaccines; a license and research collaboration agreement with Merck & Co., Inc. to research, develop, and commercialize therapeutic and prophylactic vaccine products containing its TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and Alzheimer's disease; and a research collaboration and option agreement, and a license, development, and commercialization agreement with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies.

Cougar Biotechnology has joined the fight against one beastly predator -- cancer. The development-stage company acquires and develops drug candidates for treating prostate cancer, as well as cancer affecting the blood, bone marrow, and lymph nodes. It has three candidates in early stages of development, and one that has reached the final stages of drug trials. Cougar specializes in moving candidates through development to regulatory approval. As its late-stage compound reached closer to commercial development, Cougar decided the time was right to merge with a larger entity and was acquired by Johnson & Johnson in 2009.

Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical company with a focus on cardiovascular disease. Amarin has a range of clinical and preclinical stage compounds to treat central nervous system (CNS) disorders, including Huntington’s disease, myasthenia gravis and Parkinson’s disease. Its cardiovascular programs and non-core CNS programs include AMR101, EN101, Sublingual Apomorphine and AMR 103. The Company's subsidiaries include Amarin Neuroscience Limited, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc, Amarin Finance Limited and Ester Neurosciences Limited.

Eisai Inc. develops and markets pharmaceuticals to treat a variety of ills. As the US pharmaceutical production arm of Eisai Co., its current product roster includes Alzheimer's treatment Aricept, Aciphex for acid reflux, anticoagulant Fragmin, and anti-convulsant Zonegran. It also maintains an extensive pipeline of potential drugs to address cancer, epilepsy, and severe infection. Subsidiaries Eisai Research Institute of Boston and Eisai Medical Research conduct drug development efforts in areas including oncology, neurology, and gastrointestinal ailments.

Titan Pharmaceuticals thinks big. The development-stage firm is working on drug treatments for large pharmaceutical markets, including central nervous system disorders like chronic pain, Parkinson's disease, and schizophrenia. On its own, the company is developing Probuphine, which may treat opioid addiction; Probuphine combines an already-approved chemical compound with Titan's continuous-release drug delivery technology called ProNeura. Titan is working with Vanda Pharmaceuticals on late-stage compound Iloperidone, a possible treatment for schizophrenia.

STADA Arzneimittel AG (STADA) is a Germany-based company active in the pharmaceutical sector, concentrating on the development and marketing of products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are: Generics, comprised of low-priced and active-ingredient products, and Branded Products, focusing on multisource products that are accessible without active ingredient research. STADA’s generic drugs are marketed by the Group subsidiary, STADApharm GmbH, through a sales network including Austria, Belgium, Bosnia, Portugal and the United Kingdom. Its branded products are distributed internationally as well, in such countries as Bulgaria, the Czech Republic, Denmark, Russia, Thailand and Vietnam. The Company operates through subsidiaries located in Germany, Switzerland, Russia, Macedonia, Serbia, Montenegro, Bulgaria, Romania and Poland, as well as in the United States.

Guerbet Group is one of Europe's leading makers of contrast agents used in medical imaging. Most of the company's products, such as Xenetix, Hexabrix, and Dotarem, are substances that are injected into the body to make internal organs visible during X-ray and magnetic resonance imaging (MRI) examinations. Subsidiary Simafex manufactures specialty chemicals for use in pharmaceuticals. Guerbet has operations in some 15 countries and is targeting growth in the US. Marcel Guerbet, grandfather of chairman Michel Guerbet, developed the first iodinated contrast agent around the turn of the century; his descendants control the company.

Genetix Group plc, along with its subsidiaries, is engaged in the design, development, manufacture and marketing of automated systems, services and consumables for cell biology, cytogenetics, pathology, proteomic and genomic research worldwide. The biopharmaceutical family of products include the ClonePixFL and associated reagents, which are used to identify the antibody clones that form the basis of pharmaceutical drugs. The ClonePix FL is also used to identify high-yielding cell lines for a customer’s production process. Its Cytovision systems are used worldwide for both pre and post natal genetic testing, and identifying certain forms of cancer, such as leukemia. Its Ariol system is used to image tissue samples from patients. Its wholly owned subsidiaries include Genetix Limited, Genescreen Limited, Genpak Limited, Genetix GmbH and Genetix KK. In April 2009, the Company acquired SlidePath Limited. In January 2010, Danaher Corporation acquired 97% interest in the Company.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.